- Home
- AUTL vs FFA Comparison
AUTL vs FFA Comparison
Compare AUTL & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.39
Company Overview
Basic Information| Metric | AUTL | FFA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 429.4M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | AUTL | FFA |
|---|---|---|
| Price | $1.39 | $22.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 26.1K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.72% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,128,000.00 | N/A |
| Revenue This Year | $672.42 | N/A |
| Revenue Next Year | $84.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 406.67 | N/A |
| 52 Week Low | $1.11 | $15.84 |
| 52 Week High | $2.70 | $19.30 |
Technical Indicators
Market Signals| Indicator | AUTL | FFA |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 56.27 |
| Support Level | $1.34 | $21.92 |
| Resistance Level | $1.97 | $22.13 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 5.48 | 65.57 |
Price Performance
Historical Comparison AUTL
FFA
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.